Currently, there are 604.50M common shares owned by the public and among those 564.54M shares have been available to trade.
The company’s stock has a 5-day price change of -8.25% and -18.18% over the past three months. GERN shares are trading 79.15% year to date (YTD), with the 12-month market performance up to 94.85% higher. It has a 12-month low price of $1.64 and touched a high of $5.34 over the same period. GERN has an average intraday trading volume of 8.37 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.10%, -10.96%, and -1.95% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Geron Corp (NASDAQ: GERN) shares accounts for 78.46% of the company’s 604.50M shares outstanding.
It has a market capitalization of $2.25B and a beta (3y monthly) value of 0.50. The earnings-per-share (ttm) stands at -$0.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.26% over the week and 5.09% over the month.
Analysts forecast that Geron Corp (GERN) will achieve an EPS of -0.05 for the current quarter, -0.04 for the next quarter and -0.05 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.07 while analysts give the company a high EPS estimate of -0.07. Comparatively, EPS for the current quarter was -0.09 a year ago. Earnings per share for the fiscal year are expected to increase by 17.85%, and 74.61% over the next financial year. EPS should grow at an annualized rate of 5.00% over the next five years, compared to -16.08% over the past 5-year period.
Looking at the support for the GERN, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 05, 2024, with the firm’s price target at $8. Leerink Partners was of a view on September 09, 2024 that the stock is Outperform, while Robert W. Baird gave the stock Neutral rating on April 30, 2024, issuing a price target of $4.50. TD Cowen on their part issued Buy rating on April 29, 2024.
